Amygdalin in antineoplastic medicine and the relevance of nanotechnology

Abstract

Amygdalin is a plant-based cyanogenic glycoside that has been the subject of both scientific interest and controversy for decades. Traditionally used in alternative medicine for its diverse biological activities, including anticancer, where amygdalin has been explored in complementary therapy. However, clinical utilization of amygdalin remains contentious due to concerns about its safety, primarily the release of hydrogen cyanide during its metabolism. Advancements in nanotechnology provides scope for the safe and targeted of amygdalin with improved bioavailability and targeted delivery of amygdalin, thereby, potentially eliminating the toxic effects. This review offers an update on the current research status surrounding amygdalin, with a focus on its molecular mechanisms of action, biological activities, and potential therapeutic applications. It also critically examines the challenges tied to its clinical use, particularly the safety concerns stemming from cyanide toxicity. Finally, the potential of nanotechnology in addressing cytotoxicity constraints is highlighted.